Avibactam/ceftazidime

Drug Profile

Avibactam/ceftazidime

Alternative Names: AVE 1330/ceftazidime; AVE 1330A/ceftazidime; Avibactam/ceftazidime pentahydrate; AVYCAZ; CAZ 104; CAZ-AVI; Ceftazidime pentahydrate/avibactam; Ceftazidime/AVE 1330; Ceftazidime/AVE 1330A; Ceftazidime/NXL 104; NXL 104/ceftazidime; Zavicefta

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novexel
  • Developer Allergan; AstraZeneca; Cerexa; Novexel; Pfizer
  • Class Amides; Cephalosporins; Heterocyclic bicyclo compounds; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections

Most Recent Events

  • 02 Oct 2017 Preregistration for Nosocomial pneumonia in USA (IV)
  • 02 Oct 2017 US FDA accepts sNDA for ceftazidime/avibactam for Nosocomial infections for priority review
  • 01 Jun 2017 AstraZeneca completes a phase II trial in Intra-abdominal infections (Combination therapy, In infants, In children, In adolescents) in USA, Argentina, Chile, Czech Republic, Greece, Hungary, Poland, Romania, Russia, Spain, Taiwan and Turkey (NCT02475733)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top